Lantern Pharma Inc. (LTRN) stock
LTRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.33−0.04 (-9.78%)
Close on Nov 18, 2026Market cap $4.21MP/E –Yield –
Lantern Pharma operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Lantern Pharma's operating cash flow for the twelve months ending Sep 30, 2026 was -$12.85M. For fiscal 2025 it was -$15.68M. The highest annual figure on record is -$2.13M in fiscal 2019.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$15.68M | – |
| FY2024 | Dec 31, 2024 | -$17.81M | – |
| FY2023 | Dec 31, 2023 | -$14.35M | – |
| FY2022 | Dec 31, 2022 | -$12.77M | – |
| FY2021 | Dec 31, 2021 | -$10.59M | – |
| FY2020 | Dec 31, 2020 | -$5.65M | – |
| FY2019 | Dec 31, 2019 | -$2.13M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$3.34M | – |
| Q2 FY2026 | Jun 30, 2026 | -$2.94M | – |
| Q1 FY2026 | Mar 31, 2026 | -$3.77M | – |
| Q4 FY2025 | Dec 31, 2025 | -$2.79M | – |
| Q3 FY2025 | Sep 30, 2025 | -$4.57M | – |
| Q2 FY2025 | Jun 30, 2025 | -$3.94M | – |
| Q1 FY2025 | Mar 31, 2025 | -$4.38M | – |
| Q4 FY2024 | Dec 31, 2024 | -$3.97M | – |
| Q3 FY2024 | Sep 30, 2024 | -$5.58M | – |
| Q2 FY2024 | Jun 30, 2024 | -$5.19M | – |
| Q1 FY2024 | Mar 31, 2024 | -$3.07M | – |
| Q4 FY2023 | Dec 31, 2023 | -$3.39M | – |
| Q3 FY2023 | Sep 30, 2023 | -$3.61M | – |
| Q2 FY2023 | Jun 30, 2023 | -$3.59M | – |
| Q1 FY2023 | Mar 31, 2023 | -$3.76M | – |
| Q4 FY2022 | Dec 31, 2022 | -$2.67M | – |
| Q3 FY2022 | Sep 30, 2022 | -$4.04M | – |
| Q2 FY2022 | Jun 30, 2022 | -$2.73M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.33M | – |
| Q4 FY2021 | Dec 31, 2021 | -$2.04M | – |
| Q3 FY2021 | Sep 30, 2021 | -$4.68M | – |
| Q2 FY2021 | Jun 30, 2021 | -$1.73M | – |
| Q1 FY2021 | Mar 31, 2021 | -$2.14M | – |
| Q4 FY2020 | Dec 31, 2020 | -$1.57M | – |
| Q3 FY2020 | Sep 30, 2020 | -$2.89M | – |
| Q2 FY2020 | Jun 30, 2020 | -$490.87K | – |
| Q1 FY2020 | Mar 31, 2020 | -$703.05K | – |
| Q4 FY2019 | Dec 31, 2019 | -$708.88K | – |
| Q3 FY2019 | Sep 30, 2019 | -$549.93K | – |
See a number that looks wrong?